Check out the companies making headlines in midday trading. Norwegian Cruise Line — The cruise ship operator soared 18% on strong forward guidance. Norwegian expects a profit of 12 cents per share in the current quarter, topping analysts’ consensus estimate calling for a loss of 20 cents per share, according to FactSet. Unity Software — The video game developer dropped about 9% on disappointing EBITDA guidance. Unity expects adjusted EBITDA to range between $45 million and $50 million, versus the $113 million expected by analysts polled by FactSet. Viking Therapeutics — The clinical-stage biotech soared more than 90% after fulfilling primary and secondary endpoints in its Phase 2 GLP-1 study. Viking said its Phase 2 Venture trial showed weight loss in patients receiving the VK2735 treatment. Hess Corporation — The oil and gas explorer fell 3% after Chevron warned investors that a dispute involving Exxon Mobil and China’s National Offshore Oil Corp. (Cnooc) over Guyana’s offshore oil assets threatens the planned purchase of Hess. Chevron slipped 2%. Workday — Shares slipped 3% after posting quarterly results. Earnings came in at $1.57 per share, beating expectations of $1.47 per share, according to LSEG, formerly known as Refinitiv. Revenue of $1.92 billion matched analysts’ expectations. The cloud-based software vendor also reiterated guidance for fiscal 2025. Hims & Hers — The heal …
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnCheck out the companies making headlines in midday trading. Norwegian Cruise Line — The cruise ship operator soared 18% on strong forward guidance. Norwegian expects a profit of 12 cents per share in the current quarter, topping analysts’ consensus estimate calling for a loss of 20 cents per share, according to FactSet. Unity Software — The video game developer dropped about 9% on disappointing EBITDA guidance. Unity expects adjusted EBITDA to range between $45 million and $50 million, versus the $113 million expected by analysts polled by FactSet. Viking Therapeutics — The clinical-stage biotech soared more than 90% after fulfilling primary and secondary endpoints in its Phase 2 GLP-1 study. Viking said its Phase 2 Venture trial showed weight loss in patients receiving the VK2735 treatment. Hess Corporation — The oil and gas explorer fell 3% after Chevron warned investors that a dispute involving Exxon Mobil and China’s National Offshore Oil Corp. (Cnooc) over Guyana’s offshore oil assets threatens the planned purchase of Hess. Chevron slipped 2%. Workday — Shares slipped 3% after posting quarterly results. Earnings came in at $1.57 per share, beating expectations of $1.47 per share, according to LSEG, formerly known as Refinitiv. Revenue of $1.92 billion matched analysts’ expectations. The cloud-based software vendor also reiterated guidance for fiscal 2025. Hims & Hers — The heal …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]
